Gestational diabetes & diabetes in pregnancy
Mixed Methods Randomized Controlled Trial Comparing Quality of Life for Pregnant Women With Type 1 Diabetes Using Hybrid Closed-Loop to Sensor-Augmented Pump Therapy
Authors' conclusion
These similarities demonstrate that open communication is needed between provider and patient to determine perceived benefits versus burdens of HCL use in pregnancy, especially in the United States where available HCL systems lack pregnancy-specific algorithms and Food and Drug Administration approval for pregnancy use.
Study context
- Population
- Pregnant women with T1D randomised in the Pregnancy Intervention with a Closed-Loop System study22 interviewed
- Participants
- 24 women
- Comparison
- HCL vs sensor-augmented pump therapy (SAPT) in pregnancy
- HCLn = 12
- SAPTn = 12reference
- Primary endpoint
- Quality of life in pregnancy
Methodological detailsinterviews, questionnaires
- Interviews
- Questionnaires
Primary result
As reported in the abstract
Quality of life · throughout pregnancy and early postpartum
- Quality of life was similar with HCL and SAPT
Further findings
Hypoglycemia fear
- Not statistically different between groups; improved with HCL in second trimester vs baseline
Glucose monitoring satisfaction and trust · during pregnancy
- Increased with HCL, decreased with SAPT
Device preference
- Women preferring less involvement in management preferred HCL; those desiring more involvement preferred SAPT
Original publication
Mixed Methods Randomized Controlled Trial Comparing Quality of Life for Pregnant Women With Type 1 Diabetes Using Hybrid Closed-Loop to Sensor-Augmented Pump Therapy. Endocr Pract. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →